Clinical Trial Update: Famotidine for Levodopa-induced Dyskinesia in PD [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating famotidine for levodopa-induced dyskinesia in Parkinson's disease has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Parkinson Disease

Drugs mentioned

• Famotidine (famotidine)

Snippet

Sponsor: University Health Network, Toronto | Conditions: Dyskinesia | Phase 2 | Status: COMPLETED